Nordicum - Real Estate Annual Finland 2012 | Page 63

J

The key R&D areas are drug development, diagnostics, biomaterials and functional foods. Specific areas of application include hormonal diseases and cancer, inflammatory diseases, infectious diseases, diseases of the central nervous system, as well
as regenerative medicine and biomaterials.
“A lot of the companies here have a
long testing and development phase behind
them and are now accelerating their operations also commercially,” says Turto.

ouko Turto notes that the elements needed for successful operations are all present at Turku Science Park. The compact
Science Park area features universities, numerous hi-tech companies and other service
providers in a tight mix.
“The ownership of the park in now centralised, with Turun Teknologiakiinteistöt
Oy taking care of the development of entity.”

Strong Partners
Furthermore, Turku Science Park is actively networking with national and international expertise clusters. For instance, the
Science Park has a co-operation agreement
with the German Technologiepark Heidelberg GmbH, one of the best-known clusters
of biomedical business and research expertise in Europe. In addition, Turku Science

Superstar Appeal
Turku Science Park Ltd is also acting as the
ter, which is a joint effort of the five leading
biotech centres in Finland and a part of the
Centre of Expertise Programme.
“Some of